Form 4: Rigel Pharma CMO Sells Shares Under 10b5-1 Plan

Rigel Pharmaceuticals' EVP and Chief Medical Officer, Lisa Rojkjaer, disposed of 3,758 shares of common stock at $34.62 per share under a pre-arranged 10b5-1 plan.

Summary

• Lisa Rojkjaer, Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, Inc. (RIGL), reported a transaction involving company common stock.
• She disposed of 3,758 shares of common stock on February 10, 2026.
• The shares were sold at a price of $34.62 per share.
• The transaction was executed under a Rule 10b5-1 pre-arranged trading plan, as indicated by the checked box.
• The transaction code 'F' signifies payment of exercise price or tax liability by delivering or withholding securities.
• Following this transaction, Lisa Rojkjaer directly holds 15,959 shares of Rigel Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine insider transaction for tax purposes under a pre-arranged plan, not signaling any particular positive or negative sentiment about the company's future.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage their equity compensation and tax obligations. This specific transaction is a routine 'sell to cover' for tax purposes, not indicative of a change in company fundamentals or executive sentiment.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, pre-planned transaction for tax purposes by an executive, not a significant change in ownership or a signal of company performance.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Insider Trading, Form 4, Stock Sale, Executive Compensation, Lisa Rojkjaer, 10b5-1 Plan, Biotechnology, Pharmaceuticals